Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer

ABSTRACT: Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2000mg/m2/day day1-15 Primary outcome(s): ORR;Over response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Metastatic Or Recurrent Colorectal Cancer

PROVIDER: 2626922 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 irinotecan 130mg/m2 day1 Capecitabin 1600mg/m2/day day1-15 Primary outcome(s): ORR;Overall response rate Study Design: Single arm Non-randomized

| 2627045 | ecrin-mdr-crc

Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2,000mg/m2/day day1-15 XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 200mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): ORR; Overall response rate Study Design: Parallel Randomized

| 2622964 | ecrin-mdr-crc

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx)together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Project description:Interventions: capecitabine plus intermittent oxaliplatin (CapeOx) in combination with Bevacizumab: (CapeOx + Bevacizumab)x5 cycles followed by (Capecitabine + Bevacizumab )x5 cycles, followed by (CapeOx + Bevacizumab)x5 cycles are administered until progression. [CapeOx + Bevacizumab] Capecitabine: 2000mg/m2/day p.o. (day1-15) Oxaliplatin: 130mg/m2 i.v. (day1) Bevacizumab: 7.5mg/kg i.v. (day1) to be repeated every 3 weeks [Capecitabine + Bevacizumab] Capecitabine: 2000mg/m2/day p.o. (day1-15) Bevacizumab: 7.5mg/kg i.v. (day1) to be repeated every 3 weeks Primary outcome(s): progression free survival (PFS) Study Design: Single arm Non-randomized

| 2621169 | ecrin-mdr-crc

Clinical efficacy and biomarker assessment of Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab as second-line therapy in patients with advanced or recurrent colorectal cancer after failure to irinotecan. Multi-center phase II Study.

Project description:Interventions: Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab. Capecitabine:2000mg/m2/day p.o.(day1-15) Oxaliplatin:130mg/m2 i.v.(day1) Bevacizumab:7.5mg/kg i.v.(day1) to be repeated every 3 weeks Primary outcome(s): 6-month Progression free survival rate Study Design: Single arm Non-randomized

| 2620624 | ecrin-mdr-crc

Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal cancer

Project description:Interventions: Oxaliplatin 130mg/m2 i.v.(day1) Bevacizumab 7.5mg/kg i.v.(day1) Capecitabine 2000mg/m2 p.o.(day1-14) to be repeated every 3weeks Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

| 2620414 | ecrin-mdr-crc

Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 160mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2624073 | ecrin-mdr-crc

A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.

Project description:Interventions: mtTFA(+):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(+):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Oxaliplatin 130mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine2,000mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression mtTFA(-):Irinotecan 200mg/m2 i.v. (day1) Bevaciumab 7.5mg/Kg i.v. (day1) Capecitabine1,600mg/m2 p.o.(day1-14) to be repeated every 3 weeks until progression Primary outcome(s): Response rate with or without mtTFA expression Study Design: Parallel Randomized

| 2620502 | ecrin-mdr-crc

Prospective cohort study of optimal discontinuation of oxaliplatin in elderly patients treated with XELOX plus bevacizumab

Project description:Interventions: XELOX+BEV Capecitabine:2000mg/m2 d1-14 Oxaliplatin:130mg/m2 d1 Bevacizumab:7.5mg/kg d1 Q3w Discontinuation of oxaliplatin when neurotoxicity develops >=Grade2 Primary outcome(s): Rate of Grade3 neuropathy Study Design: Single arm Non-randomized

| 2631347 | ecrin-mdr-crc

Randomized phase II study of oxaliplatin reintroduction and the biweekly XELOX in previously treated patients with metastatic colorectal cancer (ORION study)

Project description:Interventions: Oxaliplatin 130mg/m2 day1 Capacitabine 2000mg/m2 day1-14 every 3 weeks Oxaliplatin 85mg/m2 day1 Capacitabine 2000mg/m2 day1-7 every 2 weeks Primary outcome(s): time to treatment failure Study Design: Parallel Randomized

| 2619574 | ecrin-mdr-crc

A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab

Project description:Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen. Primary outcome(s): Progression-free Survival Study Design: Single arm Non-randomized

| 2622829 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data